Browse Category

Investment Analysis News 7 December 2025

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Updated: December 7, 2025 Merck & Co., Inc. (NYSE: MRK) — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt
Upstart Stock (UPST) in December 2025: Can the AI Lender Turn Explosive Growth Into Sustainable Gains?

Upstart Stock (UPST) in December 2025: Can the AI Lender Turn Explosive Growth Into Sustainable Gains?

As of 7 December 2025, Upstart Holdings (NASDAQ: UPST) sits right back in the market’s spotlight. The AI-powered consumer lender has delivered its strongest growth in years, secured multi‑billion‑dollar funding lines, and returned to GAAP profitability – yet its stock
Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Updated December 7, 2025 – for information only, not investment advice. Novo Nordisk stock today: from market darling to turnaround story Novo Nordisk (NYSE: NVO), the Danish giant behind GLP‑1 blockbusters Wegovy and Ozempic, has gone from Europe’s most valuable
1 82 83 84 85 86 161
Go toTop